YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation for Effectiveness and Tolerance Duration of Initial Medication on Untreated Early Parkinson's Disease

조기 진단 파킨슨병 환자 최초 약물의 유효성 및 약물 내성 기간에 대한 평가

  • Cheon, Young Ju (College of Pharmacy, The Catholic University of Korea) ;
  • Park, Yong Sung (Department of Radiology, Kyunghee University Hospital at Gang-dong) ;
  • Kim, Jung Tae (Department of Pharmacy, Kyunghee University Hospital at Gang-dong) ;
  • Lim, Sung Cil (College of Pharmacy, The Catholic University of Korea)
  • 천영주 (가톨릭대학교 약학대학, 임상약학연구실) ;
  • 박용성 (강동경희대학교병원 영상의학과) ;
  • 김정태 (강동경희대학교병원 약제부) ;
  • 임성실 (가톨릭대학교 약학대학, 임상약학연구실)
  • Received : 2015.04.30
  • Accepted : 2015.06.10
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to investigate the correlation among age, symptoms and initial medication (IM), and the tolerance duration of IM in Korean people with Parkinson's disease (PD). We studied 60 patients with untreated early PD who were initially diagnosed in our hospital between Jun 2006 and Sep 2014. We collected data on sex, age at diagnosis, symptom duration until diagnosis, main motor symptoms, frequency and duration of IM through electronic medical records. We divided patients into groups depending on the number of drugs (MONO/COMBI) and whether to contain dopaminergic property (DOPA/NDOPA). We analyzed the correlation between age and symptoms in each two groups and calculated the mean tolerance duration of IM in each of the groups. The mean symptom duration until diagnosis was 12.2 months. The most frequent drug was levodopa formulations (80%) compared to dopamine agonists (58.3%). The number of patients in the COMBI group (63.3%) was more than that in the MONO group (36.7%). Half of the patients in the COMBI group were taking LDF+DA (50%). Except for tremor, no other symptom showed a significant correlation between with IM. The mean tolerance duration of IM was within 200 days. The mean duration for COMBI group (342.7 days) was longer than that for MONO group (209.8 days). Among regimens, the mean tolerance duration of DOPA group (293.3 days) was longer than for NDOPA group (251.4 days). There was no difference in survival curves between any of the two groups. We found that patients experienced symptoms for over a year in Korea. This indicates that diagnosis time is faster than reported in other previous studies. The longest tolerance duration among IM was for dopaminergic combination therapy. More research is needed to design the most appropriate treatment for PD in Korean patients.

Keywords

References

  1. Cheong, H. K., Lee, C. S., Kim, Y. H., Sung, J. H., Yi, S. E., Kim, J. W., Park, J. S., Kim, E. H., Kim, J. H., Jang, M. S. and Shim, M. Y. : Nationwide survey on the prevalence of Parkinson's disease in Korea. Korea Centers for Disease Control and Prevention (2007).
  2. Homepage of Korea Centers for Disease Control and Prevention. URL=http://www.cdc.go.kr/CDC/cms/content/37/16537_view.html.
  3. Parkinson study group : Pramipexole vs. levodopa as initial treatment for Parkinson disease, a randomized controlled study. JAMA 284, 1931 (2000). https://doi.org/10.1001/jama.284.15.1931
  4. Miyasaki, J. M., Martin, W., Suchowersky, O., Weiner, W. J. and Lang, A. E. : Practice parameter: initiation of treatment for Parkinson's disease: An evidence-based review. Neurology 58, 11 (2002). https://doi.org/10.1212/WNL.58.1.11
  5. Tarsy, D. :Initial treatment of Parkinson's disease. Curr. Treat. Options Neurol. 8, 224 (2006). https://doi.org/10.1007/s11940-006-0013-y
  6. Connolly, B. S. and Lang, A. E. : Pharmacological treatment of Parkinson disease - A Review. JAMA 311, 1670 (2014). https://doi.org/10.1001/jama.2014.3654
  7. Tarsy, D., Hurtig, H. I. and Dashe, J. F. : Pharmacologic treatment of Parkinson disease. Uptodate, the last updated Jul (2014) URL=http://www.uptodate.com/contents/pharmacologic-treatment-of-parkinson-disease#H2.
  8. Szewczyk-Krolikowsk, K., Tomlinson, P., Nithi, K., Wade-Martins, R., Talbot, K., Ben-Shlomo, Y. and Hu, M. T. : The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsononism Relat. Disord. 20, 99 (2014). https://doi.org/10.1016/j.parkreldis.2013.09.025
  9. NICE (National Institute for health and Care Excellence guideline) : Parkinson's disease, NICE guidelines [CG35]. published date : June 2006, Review decision date : July 2011, URL=http://www.nice.org.uk/guidance/cg035.
  10. Pahwa, R. and Lyons, K. E. : Early diagnosis of Parkinson's disease: Recommendations from diagnostic clinical guidelines. Am. J. Manag. Care 16, S94 (2010).
  11. Hauser, R. A. : Early pharmacologic treatment in Parkinson's disease. Am. J. Mang. Care 16, S100 (2010).
  12. Fahn, S. : Is levodopa toxic? Neurology 47, S184 (1996). https://doi.org/10.1212/WNL.47.6_Suppl_3.184S
  13. The Parkinson Study Group : Levodopa and the progression of Parkinson's disease. N. Eng. J. Med. 351, 2498 (2004). https://doi.org/10.1056/NEJMoa033447
  14. EFNS/MDS-ES (European Federation of Neurological Societies/Movement disorder Society-European Section) guidelines : Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur. J. Neurol. 20, 5 (2013). https://doi.org/10.1111/j.1468-1331.2012.03866.x
  15. Nutt, J. G. and Wooten, G. F. : Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353, 1021 (2005). https://doi.org/10.1056/NEJMcp043908
  16. Chu, M. K., Kim, W. C., Choi, J. M., Hong, J. H., Kang, S. Y., Ma, H. I. and Kim, Y. J. : Analysis of dosage mutation in PARK2 among Korean patients with early-onset or familial Parkinson's disease. J. Clin. Neurol. 10, 244 (2014). https://doi.org/10.3988/jcn.2014.10.3.244
  17. Fujio, H., Inokuchi, G., Fukuda, Y., Hasegawa, S., Ootsuki, N. and Nibu, K. : A case report of Parkinson's disease presenting with olfactory disturbance as a primary symptom in the early stage. Nihon Jibiinkoka GakkaiKaiho 117, 932 (2014). https://doi.org/10.3950/jibiinkoka.117.932
  18. Siuda, J., Jasinska-Myga, B., Boczarska-Jedynak, M., Opala, G., Fiesel, F. C., Moussaud-Lamodière, E. L., Scarffe, L. A., Dawson, V. L., Ross, O. A., Springer, W., Dawson, T. M. and Wszolek, Z. K. : Early-onset Parkinson's disease due to PINK1 p.Q456X mutation - Clinical and functional study. Parkinsonism Relat. Disord. 20, 1274 (2014). https://doi.org/10.1016/j.parkreldis.2014.08.019
  19. 한국임상약학회 : 약물치료학 요약집 2014, 1st ed., 도서출판 신일북스. 서울 p. 402 (2014).

Cited by

  1. 허증(虛證)으로 변증한 구순 및 하악 진전환자의 한의학적 치료 6례 vol.26, pp.3, 2015, https://doi.org/10.7231/jon.2015.26.3.267
  2. 소양인 파킨슨병 환자의 한양방 병행치료 장기 경과관찰 보고 3례 vol.28, pp.4, 2016, https://doi.org/10.7730/jscm.2016.28.4.361
  3. 심화상염(心火上炎)으로 진단된 설통(舌痛)과 구강안면부 진전(振顫)의 세심약침을 이용한 한의치료 1례 vol.38, pp.5, 2017, https://doi.org/10.22246/jikm.2017.38.5.564
  4. 태음인 조열증으로 진단한 파킨슨병 환자의 치험 1례 vol.29, pp.4, 2015, https://doi.org/10.7730/jscm.2017.29.4.376
  5. 일개 한방병원에 파킨슨병으로 내원한 환자의 사상의학적 특성에 관한 고찰 vol.30, pp.3, 2018, https://doi.org/10.7730/jscm.2018.30.3.62